Cancer research groups partner for liquid biopsy trial

By The Science Advisory Board staff writers

July 30, 2020 -- The Cancer Research Institute and the Mark Foundation for Cancer Research have partnered on a clinical trial to evaluate whether a novel liquid biopsy diagnostic can assess immune response in cancer patients.

In a phase II, multicenter trial, researchers from the Canadian Cancer Trial Group will first investigate whether changes in circulating cell-free tumor DNA (ctDNA) can better predict immunotherapy response than radiographic assessments. They will then examine whether ctDNA patterns can guide treatment decisions for patients with non-small cell lung cancer.

The trial will be conducted at six sites in Canada and the U.S. and is expected to be completed in December 2021. It is being chaired by Dr. Valsamo Anagnostou, PhD, an assistant professor of oncology at Johns Hopkins whose previous research has demonstrated that ctCNA levels can predict clinical response.

Thermo Fisher set to acquire Qiagen after all in $11.5B deal
After an on-and-off courtship, Thermo Fisher Scientific announced it is set to acquire Qiagen in a deal worth $11.5 billion. The transaction will...
MilliporeSigma to make Elypta liquid biopsy kits
MilliporeSigma has signed an agreement with Swedish molecular diagnostics company Elypta to be the contract manufacturer for Elypta's clinical diagnostic...
LabCorp adopts Thermo Fisher NGS for companion diagnostics
LabCorp announced on January 14 that it will adopt Thermo Fisher Scientific's Ion Torrent Genexus next-generation sequencing (NGS) system and Oncomine...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
ESMO Virtual Congress 2020
September 14-29
2020 ACCP Annual Meeting
September 20-22
BioProcess International West
September 21-25
BioProcess International
September 21-25
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter